C-Suite Challenges And How Intellectual Property Can Help Meet Them

The 2018 C-Suite Challenges in Life Sciences Survey from Biotech & Money/LSX paints a positive picture of the biotech economy. With 34% of respondents having recently received seed investment, and a further 35% having received series A and B investment – the start-up and SME scene is clearly in rude health.

At the other end of the market too, 16% of respondents reported their most recent financing round as being an IPO or second and follow-on offering.

The growth and investment we are seeing in this sector is being driven by the big health challenges of our time. Almost one-quarter (23%) of respondents, for example, are in the field of neurology and 17% in cardiovascular – with biotech companies looking to meet the challenges associated with an ageing population. Also reflecting contemporary health concerns, 29% of respondents are in the field of oncology.